Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 29:7:72-80.
doi: 10.33393/grhta.2020.2140. eCollection 2020 Jan-Dec.

Analisi di budget impact di anakinra nel trattamento della Malattia di Still in Italia

[Article in Italian]
Roberto Ravasio  1 , Roberto Giacomelli  2 , Stefano Bianchi  3
Affiliations

Analisi di budget impact di anakinra nel trattamento della Malattia di Still in Italia

[Article in Italian]
Roberto Ravasio et al. Glob Reg Health Technol Assess. .

Erratum in

Abstract

Background:: Anakinra, canakinumab and tocilizumab are all effective alternative treatment choice in patients with Still’s disease including both systemic juvenile idiopathic arthritis (SJIA) and adult onset Still’s disease (AOSD).

Objective:: Aim of this study was to estimate the budget impact of the use of anakinra compared to canakinumab and tocilizumab in the treatment of patients with AOSD or SJIA.

Methods:: Considering the perspective of the Italian National Health Service (iNHS), a budget impact model (BIM) was developed to estimate the drug costs of anakinra, canakinumab and tocilizumab up to 12 months. The BIM showed the difference of drug expenditure generated by the base case calculated for current prescription volumes, and for different prescription volume scenarios with increased anakinra prescription. Key variables were tested in the sensitivity analysis.

Results:: Compared to the current scenario for SJIA, an increase in the market share of anakinra (40% or 50%) would lead to a reduction in the drug expenditure sustained by iNHS (–€1,087,494 [–12.4%] or –€2,023,990 [–23.1%]). Compared to the current scenario for AOSD, an increase in the market share of anakinra (40% or 50%) would lead to a reduction in the drug expenditure sustained by iNHS (–€4,024,585 [–13.5%] or –€8,049,169 [–27.0%]).

Conclusion:: According to the present analysis, the use of anakinra, as an alternative to canakinumab or tocilizumab in patients with AOSD or SJIA, could represent a cost-saving option for the iNHS.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The Authors declare that they have no conflicts of interest in this research.

Figures

Fig. 1 -
Fig. 1 -
Struttura del modello di budget impact.
Fig. 2-
Fig. 2-
Risultati dell’analisi di budget impact per SJIA.
Fig. 3 -
Fig. 3 -
Risultati dell’analisi di budget impact per AOSD.
See this image and copyright information in PMC

References

    1. Sfriso P, Bindoli S, Galozzi P. Adult-onset Still’s disease: molecular pathophysiology and therapeutic advances. Drugs. 2018;78(12):1187–95. - PubMed
    1. Zhou S, Qiao J, Bai J et al. Biological therapy of traditional therapy-resistant adult-onset Still’s disease: an evidence-based review. Ther Clin Risk Manag. 2018;14:167–71. - PMC - PubMed
    1. Sfriso P, Priori R, Valesini G et al. Adult onset Still’s disease: an Italian multicenter retrospective observational study of manifestations and treatments in 245 patients. Clin Rheumatol. 2016;35(7):1683–9. - PubMed
    1. Arthur VL, Shuldiner E, Remmers EF et al. IL1RN variation influences both disease susceptibility and response to recombinant human interleukin-1 receptor antagonist therapy in systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2018;70(8):1319–30. - PMC - PubMed
    1. Nirmala N, Brachat A, Feist E et al. Gene-expression analysis of adult-onset Still’s disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity. Pediatr Rheumatol Online J. 2015;13:50. - PMC - PubMed

LinkOut - more resources